Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety of PZ-128 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention- Thrombin Receptor Inhibitory Pepducin in PCI (TRIP-PCI)
NCT02561000 is registered in ClinicalTrials.gov with Tufts Medical Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety of PZ-128 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention- Thrombin Receptor Inhibitory Pepducin in PCI (TRIP-PCI)
- Lead sponsor
- Tufts Medical Center
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- May 27, 2016
- Completion date
- September 17, 2019
- Enrollment
- 100 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.